Press Release Summary (December 11, 2024):
Minoryx Therapeutics, a late-stage biotech company, and Neuraxpharm Group, a European specialty pharmaceutical firm, announced positive outcomes from the NEXUS trial, a pivotal 96-week study evaluating leriglitazone in pediatric patients with cerebral Adrenoleukodystrophy (cALD). The trial demonstrated a significant 35% arrest of disease progression in treated patients, compared to only 10% observed in the natural course of the disease. Importantly, leriglitazone was well-tolerated, with no serious adverse events reported during the study.
Both companies plan to file for European Marketing Authorization (MAA) for pediatric and adult cALD patients by mid-2025. This development offers a vital, non-invasive treatment option for a devastating neurodegenerative condition, addressing the critical unmet need for therapies beyond the invasive and limited availability of hematopoietic stem cell transplantation.
Marc Martinell, CEO of Minoryx, and Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm, emphasized the transformative potential of leriglitazone in improving outcomes for patients facing this fatal condition. These findings will be presented at upcoming neurology conferences, while efforts to secure regulatory approvals and expand clinical trials for related indications are ongoing.
This summary is based on a press release authored by Minoryx Therapeutics and Neuraxpharm Group. For more information, visit Minoryx Therapeutics or Neuraxpharm.
View full press release here
*The United Leukodystrophy Foundation is not liable for any inaccuracies or gaps in these overviews , which are offered “as is” without assurances on completeness, accuracy, or timeliness. For verification or detailed information, please consult the original articles directly.
As a leukodystrophy related nonprofit, the ULF provides awareness to scientific literature. Inclusion on our website does not imply endorsement of, or agreement with, the contents by the ULF.